{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04973657",
            "orgStudyIdInfo": {
                "id": "VK0214-102"
            },
            "organization": {
                "fullName": "Viking Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN",
            "officialTitle": "Phase 1b, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, PD and PK of VK0214, in Subjects With the Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "a-study-to-assess-the-pharmacodynamics-of-in-male-subjects-with-amn"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-06-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-06-28",
            "studyFirstSubmitQcDate": "2021-07-21",
            "studyFirstPostDateStruct": {
                "date": "2021-07-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-18",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Viking Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Subjects will be administered multiple doses of VK0214 in a cohort dose escalation process. A total of up to 36 subjects will be enrolled in the study, into one of three dose cohorts. For each cohort, up to 12 subjects will be randomized to receive VK0214 or placebo in a 3:1 ratio so that there will be a total of up to 9 subjects for each of the active doses and up to 3 subjects dosed with placebo in each cohort.",
            "detailedDescription": "The first part of VK0214-102 will include the first 2 dose cohorts and placebo, which will be dosed in parallel (up to N=24). The first 2 doses used in these cohorts will be 20 mg QD and 40 mg QD for 28 days. A Dose Level Review Team (DLRT) meeting will be held at the end of the first 2 parallel doses.\n\nThe DLRT will review safety, tolerability, and preliminary efficacy data from cohort 1 and 2. If the data analyzed show that the first 2 doses are safe and well tolerated the DLRT may make a recommendation for proceeding to commence dosing in the third dose cohort.\n\nBased upon outcomes in Cohorts 1 and 2, the sponsor may decide to include a third dose cohort. Before screening may be initiated in Cohort 3, data to support dosing in this cohort will be submitted to the FDA, together with the amended protocol and the dosing recommendation of the DLRT."
        },
        "conditionsModule": {
            "conditions": [
                "Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)"
            ],
            "keywords": [
                "AMN, XALD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 36,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "VK0214 Active 20mg",
                    "type": "EXPERIMENTAL",
                    "description": "20mg QD",
                    "interventionNames": [
                        "Drug: VK0214"
                    ]
                },
                {
                    "label": "VK0214 Active 40mg",
                    "type": "EXPERIMENTAL",
                    "description": "40mg QD",
                    "interventionNames": [
                        "Drug: VK0214"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo QD",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "VK0214",
                    "description": "API in capsule",
                    "armGroupLabels": [
                        "VK0214 Active 20mg",
                        "VK0214 Active 40mg"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "API in capsule",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)",
                    "description": "Evaluate the safety and tolerability of multiple oral doses of VK0214 in subjects with AMN",
                    "timeFrame": "28 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluate the Pharmacokinetics of VK0214",
                    "description": "Pharmacokinetic profile of VK0214 by measuring Peak Plasma Concentration (Cmax)",
                    "timeFrame": "28 days"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Evaluate plasma VLCFAs changes",
                    "description": "Evaluate the efficacy of VK0214 on lowering plasma levels of VLCFAs in subjects with AMN",
                    "timeFrame": "28 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Provide a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and is willing and able to participate.\n* Have diagnosis of X-linked adrenoleukodystrophy (X-ALD) by genetic testing and elevated VLCFAs.\n* Present clinical features of AMN, or adrenal insufficiency.\n* Subjects must be 18 years of age and older.\n\nExclusion Criteria:\n\n* Have the cerebral form of X-ALD, based on medical records, or based on MRI performed within the last 12 months or MRI at screening\n* Have been treated with any drug targeting TR\u03b2 or with any drug being tested as therapy for X-ALD AMN form within the past 30 days before screening\n* History or presence of clinically significant acute or unstable hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological or oncological that in the opinion of the investigator would pose a significant risk for the subject\n* Subject has untreated primary adrenal insufficiency based on morning plasma cortisol and ACTH at screening\n* Lorenzo's Oil. Currently taking Lorenzo's Oil or erucic acid containing product, or other lipid lowering agent known to effect VLCFA levels",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephanie Herman",
                    "role": "CONTACT",
                    "phone": "858-704-4694",
                    "email": "sherman@vikingtherapeutics.com"
                },
                {
                    "name": "Marianne Mancini",
                    "role": "CONTACT",
                    "phone": "858-704-4674",
                    "email": "mmancini@vikingtherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Viking Clinical Site 203",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94303",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                },
                {
                    "facility": "Viking Clinical Site 207",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32610",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                },
                {
                    "facility": "Viking Clinical Site 201",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Viking Clinical Site 205",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Viking Clinical Site 214",
                    "status": "RECRUITING",
                    "city": "Bordeaux",
                    "zip": "33076",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "Viking Clinical Site 215",
                    "status": "RECRUITING",
                    "city": "Montpellier",
                    "zip": "34295",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.61092,
                        "lon": 3.87723
                    }
                },
                {
                    "facility": "Viking Clinical Site 209",
                    "status": "RECRUITING",
                    "city": "Leipzig",
                    "zip": "04103",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.33962,
                        "lon": 12.37129
                    }
                },
                {
                    "facility": "Viking Clinical Site 210",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "zip": "20133",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Viking Clinical Site 212",
                    "status": "NOT_YET_RECRUITING",
                    "city": "London",
                    "zip": "WC1N3BG",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000326",
                    "term": "Adrenoleukodystrophy"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020739",
                    "term": "Brain Diseases, Metabolic, Inborn"
                },
                {
                    "id": "D000001928",
                    "term": "Brain Diseases, Metabolic"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000020279",
                    "term": "Hereditary Central Nervous System Demyelinating Diseases"
                },
                {
                    "id": "D000056784",
                    "term": "Leukoencephalopathies"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000038901",
                    "term": "Mental Retardation, X-Linked"
                },
                {
                    "id": "D000008607",
                    "term": "Intellectual Disability"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000040181",
                    "term": "Genetic Diseases, X-Linked"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000020271",
                    "term": "Heredodegenerative Disorders, Nervous System"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000018901",
                    "term": "Peroxisomal Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000000309",
                    "term": "Adrenal Insufficiency"
                },
                {
                    "id": "D000000307",
                    "term": "Adrenal Gland Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3677",
                    "name": "Adrenoleukodystrophy",
                    "asFound": "Adrenoleukodystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5205",
                    "name": "Brain Diseases, Metabolic",
                    "relevance": "LOW"
                },
                {
                    "id": "M22498",
                    "name": "Brain Diseases, Metabolic, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22099",
                    "name": "Hereditary Central Nervous System Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M28591",
                    "name": "Leukoencephalopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M11589",
                    "name": "Intellectual Disability",
                    "relevance": "LOW"
                },
                {
                    "id": "M24774",
                    "name": "Mental Retardation, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M24877",
                    "name": "Genetic Diseases, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M22092",
                    "name": "Heredodegenerative Disorders, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20939",
                    "name": "Peroxisomal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3661",
                    "name": "Adrenal Insufficiency",
                    "relevance": "LOW"
                },
                {
                    "id": "M3659",
                    "name": "Adrenal Gland Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T218",
                    "name": "Adrenomyeloneuropathy",
                    "asFound": "Adrenomyeloneuropathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5954",
                    "name": "X-linked Adrenoleukodystrophy",
                    "asFound": "X-linked Adrenoleukodystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4503",
                    "name": "Peroxisomal Biogenesis Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}